Feb 22, 2022
Hamid Khoja is the Chief Scientific Officer of FibroBiologics which is developing regenerative medicine using fibroblasts which are one of the most abundant cells in the human body. While stem cell therapy has gotten significant attention, fibroblasts are easier to source and grow.
Hamid elaborates, "Just to give you a sense of some of the capabilities of fibroblasts. They behave very similarly in many aspects to stem cells, which we're very well aware of. What makes fibroblasts significantly interesting for us and for therapeutic purposes is that they can also differentiate into many different cell types."
"So the CybroCell is the product name that we've given our tolerogenic fibroblasts, cells that have been specifically cultured for use in degenerative disc disease. But we've also tested this same product in a clinical trial for multiple sclerosis. So we have done limited trials for safety for both degenerative disc disease and multiple sclerosis, and the results have been very promising."
#FibroBiologics #Fibroblasts #DegenerativeDiscDisease #DDD #MultipleSclerosis #MS #MultipleSclerosisTreatment #StemCellAlternative
